Skip to content

Study · Animal study (in vivo) · rat · 1989

5 results

Attenuation of SCH 23390-induced alteration of striatal dopamine D1 receptor ontogeny by prolyl-leucyl-glycinamide in the rat.

Kostrzewa RM, Saleh MI

Neuropharmacology1 Aug 1989Cited by 5 (Europe PMC)

PMID2571103 (opens in a new tab)DOI10.1016/0028-3908(89)90171-8 (opens in a new tab)PepBankPUB-02571103
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rats, striatal SCH 23390 binding after PLG plus SCH 23390 was unchanged from control at 8 weeks.

    In plain wordsIn rats, PLG plus SCH 23390 produced striatal binding similar to controls.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeStriatal SCH 23390 binding at 8 weeks
    Study

    ratn: not reported in source

    postnatal striatal dopamine receptor development
    Comparator
    control
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    1.0 mg/kg/d · intraperitoneal · 32 days from birthAs given in this study (rat).

    Source sentences

    Summary
    When PLG (1.0 mg/kg/d.i.p.) was administered together with SCH 23390 for the initial 32 days from birth, the binding of [3H]SCH 23390 to homogenates of the striatum was unchanged from that of the control group at 8 weeks.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats, striatal binding Bmax after SCH 23390 plus PLG was unchanged from control at 5 weeks.

    In plain wordsIn rats, SCH 23390 plus PLG produced receptor binding capacity similar to controls.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeSCH 23390 binding Bmax at 5 weeks
    Study

    ratn: not reported in source

    postnatal striatal dopamine receptor development
    Comparator
    control
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    1.0 mg/kg/d · intraperitoneal · 32 days from birthAs given in this study (rat).

    Source sentences

    Summary
    Also, at 5 weeks the Bmax and Kd were unaltered from control in the group that was treated with both SCH 23390 and PLG.
    1 context sentence
    Summary · context
    When PLG (1.0 mg/kg/d.i.p.) was administered together with SCH 23390 for the initial 32 days from birth, the binding of [3H]SCH 23390 to homogenates of the striatum was unchanged from that of the control group at 8 weeks.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats, striatal binding Kd after SCH 23390 plus PLG was unchanged from control at 5 weeks.

    In plain wordsIn rats, SCH 23390 plus PLG produced receptor binding affinity similar to controls.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeSCH 23390 binding Kd at 5 weeks
    Study

    ratn: not reported in source

    postnatal striatal dopamine receptor development
    Comparator
    control
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    1.0 mg/kg/d · intraperitoneal · 32 days from birthAs given in this study (rat).

    Source sentences

    Summary
    Also, at 5 weeks the Bmax and Kd were unaltered from control in the group that was treated with both SCH 23390 and PLG.
    1 context sentence
    Summary · context
    When PLG (1.0 mg/kg/d.i.p.) was administered together with SCH 23390 for the initial 32 days from birth, the binding of [3H]SCH 23390 to homogenates of the striatum was unchanged from that of the control group at 8 weeks.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats, PLG alone did not alter striatal SCH 23390 binding compared with control.

    In plain wordsIn rats, PLG alone did not change striatal receptor binding compared with controls.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeSCH 23390 binding with PLG alone
    Study

    ratn: not reported in source

    postnatal striatal dopamine receptor development
    Comparator
    control
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The binding of [3H]SCH 23390 was not altered from control in the group treated with PLG alone.
  5. 05LabEx vivo tissueMechanism

    In rat striatal homogenates, PLG did not alter SCH 23390 binding compared with control.

    In plain wordsIn lab tests, PLG did not change receptor binding in rat striatal homogenates compared with controls.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeSCH 23390 binding in vitro
    Study

    ratn: not reported in source

    control rat striatal homogenates
    Comparator
    control
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Also, PLG given in vitro did not alter the binding of [3H]SCH 23390 to control homogenates of the striatum.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.